Carenoprazan hydrochloride is under clinical development by Jiangsu Carephar Pharmaceutical and currently in Phase III for Reflux Esophagitis (Gastroesophageal Reflux Disease). According to GlobalData, Phase III drugs for Reflux Esophagitis (Gastroesophageal Reflux Disease) have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Carenoprazan hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Carenoprazan hydrochloride overview
Carenoprazan hydrochloride is a new-generation candidate acts by targeting potassium ions. It is formulated as tablets for oral route of administration. Carenoprazan hydrochloride is indicated for the treatment of duodenal ulcer and reflux esophagitis.
Carenoprazan hydrochloride is under development for the treatment of peptic ulcers, gastric ulcer, duodenal ulcer and reflux esophagitis. It is administered through oral route as tablets and parenteral route. It is a new-generation candidate acts by targeting potassium ions. The drug candidate is a potassium-competitive acid blocker (P-CAB).
For a complete picture of Carenoprazan hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.